Intraperitoneal chemotherapy for ovarian carcinoma: Results of long-term follow-up Journal Article


Authors: Barakat, R. R.; Sabbatini, P.; Bhaskaran, D.; Revzin, M.; Smith, A.; Venkatraman, E.; Aghajanian, C.; Hensley, M.; Soignet, S.; Brown, C.; Soslow, R.; Markman, M.; Hoskins, W. J.; Spriggs, D.
Article Title: Intraperitoneal chemotherapy for ovarian carcinoma: Results of long-term follow-up
Abstract: Purpose: To determine long-term survival and predictors of recurrence in a retrospective cohort of patients with epithelial ovarian cancer treated with intraperitoneal (IP) chemotherapy. Patients and Methods: Records were reviewed of 433 patients who received IP therapy for ovarian cancer between 1984 and 1998; follow-up data were available for 411 patients. IP therapy was provided as consolidation therapy (n = 89), or for treatment of persistent (n = 310) or recurrent (n = 12) disease after surgery and initial systemic therapy; therapy usually consisted of platinum-based combination therapy. Statistical analysis included tests for associations between potential prognostic factors, and between prognostic factors and survival. Survival probabilities were estimated by Kaplan-Meier methods, and prognostic factors for survival were evaluated by a Cox proportional hazard model. Results: The mean age of patients was 52 years (range, 25 to 76 years). Distribution by stage and grade was as follows: stage I, 7; II, 24; III, 342; IV, 52; not available (NA), 8; and grade 1, 30; 2, 99; and 3, 289; NA, 15. The median survival from initiation of IP therapy by residual disease was none, 8.7 years; microscopic, 4.8 years; less than 1 cm, 3.3 years; more than 1 cm, 1.2 years. In a multivariate analysis, the only significant predictors of long-term survival were grade and size of residual disease at initiation of IP therapy. Conclusion: Prolonged survival was observed in selected patients receiving IP platinum-based therapy. It is not possible to determine the contribution of IP therapy to survival in this study. A relationship between size of disease at the initiation of IP therapy and long-term survival was demonstrated. © 2002 by American Society of Clinical Oncology.
Keywords: adult; cancer survival; treatment outcome; aged; middle aged; retrospective studies; major clinical study; cancer recurrence; fluorouracil; cancer combination chemotherapy; gemcitabine; paclitaxel; combined modality therapy; cytarabine; cancer staging; follow up; follow-up studies; antineoplastic agent; neoplasm staging; cancer grading; intraoperative care; adenocarcinoma; ovarian neoplasms; ovary cancer; etoposide; minimal residual disease; mitoxantrone; ovary carcinoma; platinum; multivariate analysis; kaplan meier method; floxuridine; humans; prognosis; human; female; priority journal; article
Journal Title: Journal of Clinical Oncology
Volume: 20
Issue: 3
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2002-02-01
Start Page: 694
End Page: 698
Language: English
DOI: 10.1200/jco.20.3.694
PUBMED: 11821450
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 14 November 2014 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Venkatraman Ennapadam Seshan
    285 Seshan
  2. William Hoskins
    137 Hoskins
  3. Richard R Barakat
    588 Barakat
  4. Carol Brown
    116 Brown
  5. Steven L Soignet
    52 Soignet
  6. Alexander D Smith
    28 Smith
  7. Paul J Sabbatini
    199 Sabbatini
  8. Martee L Hensley
    220 Hensley
  9. Robert Soslow
    641 Soslow
  10. David R Spriggs
    312 Spriggs